Future pre-clinical and possibly clinical studies will be needed to assess the use of dacomitinib or other EGFR TKI’s as a treatment strategy for lung cancer patients, and potentially glioblastoma patients, whose cancers harbor EGFR ECD variants. This evidence concerns the gene EGFR and glioblastoma.